Lupin Ltd News

Q3 results today: Lupin, Vodafone Idea, IRCTC to post earnings on Feb 11

Q3 FY25 company results, Feb 11: MOIL, Berger Paints, IIFL Securities, and Schneider Electric Infrastructure will be among 334 companies to release their performance report for the Oct-Dec quarter

Alkem Labs, Ipca, Divi's: Three reasons why pharma stocks are falling today

Stocks such as Natco, Dr. Reddy's, Cipla, Mankind, Torrent, Sun Pharma, Abbott, and Glenmark slipped in the range of 1-2 per cent

Lupin, Hindalco: 3 stocks to buy today by Ajit Mishra of Religare Broking

Nifty 50 Today: The Nifty index may continue to consolidate after its recent surge, but the broader trend remains positive

Lupin surges 8% in 2 days on USFDA nod for generic HIC drug

The drugs include Darunavir, Cobicistat, Emtricitabine, and Tenofovir Alafenamide tablets and the company is the exclusive first-to-file for this products

Lupin receives USFDA approval to market its generic HIV medications

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) under the US President's Emergency Plan for AIDS Relief (PEPFAR) for Abacavir, Dolutegravir and Lamivudine tablets, the Mumbai-base drug maker said in a statement. The company's product is a generic equivalent of ViiV Healthcare Company's Triumeq PD tablets for oral suspension, it added. This product would be manufactured at the drug firm's Nagpur facility and will be supplied to low-and middle-income countries, it said. The fixed-dose combination of Abacavir 60 mg/Dolutegravir 5 mg/Lamivudine 30 mg tablets for oral suspension is a once-daily single-pill regimen, indicated for the treatment of HIV-1 infection in pediatric patients aged at least 3 months and weighing at least 6 kg. "The tentative approval from the USFDA for our Abacavir, Dolutegravir and

Lupin shares rise but pares gains soon; here's what moved stock in trade

The EIR was issued with an inspection classification of Voluntary Action Indicated (VAI) post the inspection of the facility from September 16 to September 27, 2024

Lupin, IREDA, AWL: These 4 buzzing stocks can rally up to 28%; hint charts

IREDA stock is seen attempting a breakout on the daily scale, while SJVN is testing support at the key monthly moving average, which the stock has held since August 2020; shows the technical charts.

Lupin up 2%, hits new high on buying Eli Lilly's diabetes drug Huminsulin

The stock of the pharmaceutical company, Lupin is quoting higher for the sixth straight trading day; it has rallied 10 per cent during the period

Lupin acquires Huminsulin from Lilly to strengthen diabetes portfolio

The Huminsulin range is vital for managing both type 1 and type 2 diabetes, helping control blood sugar levels in adults and children

Nifty Pharma index rallies 2% in weak market;Ipca, Dr Reddy's gain up to 6%

At 02:37 pm; Nifty Pharma, the sole gainer among sectoral indices, was up 1.8 per cent, as compared to 1 per cent decline in the Nifty 50.

Lupin shares gain 3% after USFDA approves type-2 diabetes drug; details

Lupin share price gained after the company announced that it has received tentative approval from the United States Food and Drug Administration (US FDA)

Lupin recalls over 600,000 bottles of hypertension drug in US: USFDA

Drug firm Lupin is recalling over six lakh bottles of a medication indicated for high blood pressure in the US due to deviation from current good manufacturing practices (CGMP), according to the US health regulator. As per its latest Enforcement Report, US Food and Drug Administration (USFDA), stated that Dr Reddy's Laboratoties is also recalling a product in the US due to a manufacturing issue. Baltimore-based Lupin Pharmaceuticals Inc, a subsidiary of Mumbai-based Lupin, is recalling 6,16,506 bottles of Ramipril capsules in strengths of 2.5 mg, 5 mg and 10 mg, the US health regulator said. The affected lot is manufactured at Lupin's Goa-based manufacturing facility, it stated. The company is recalling 1,12,770 bottles of 2.5 mg tablets; 1,46,322 bottles of 5 mg tablets and 3,57,414 bottles of 10 mg tablets, it said. The US health regulator noted that the company is undertaking Class II voluntary recall due to "CGMP Deviations: Active pharmaceutical ingredient was sourced from an

Stocks to Watch, Nov 8: Lupin, Cochin Shipyard, Astral, Emami, RVNL, NHPC

Stocks to watch, November 8, 2024: Cochin Shipyard reported a Q2FY25 net profit of Rs 193 crore, which is slightly lower than Rs 200 crore in the same period last year

Lupin Q2FY25 results: Net profit jumps 74% to Rs 853 cr on strong demand

Consolidated net profit of the company, which makes biosimilars and active pharmaceutical ingredients, rose to Rs 853 crore (about $101 million) for the quarter ended Sept. 30

Q2 results today: M&M, Lupin, NHPC, and RVNL among 166 to post earnings

Q2 results today, November 7: Trent, Abbott India, Aditya Birla Fashion and Retail, and more will release their Q2FY25 performance report

Lupin Q2 Preview: Profits may rise 42% YoY led by steady India, US sales

Brokerages expect Lupin to report a strong quarter on a year-on-year basis, while a quieter one sequentially

Drug firm Lupin names Claus Jepsen as President Global specialty business

Drug firm Lupin on Monday said it has appointed Claus Jepsen as President, Global Specialty business. Jepsen joins Lupin from Takeda Pharmaceuticals, where he led the Global Strategy for rare diseases. "His experience in leading specialty strategy, commercial planning and portfolio choices across key markets will enable us to build our Specialty brand business," Lupin CEO Vinita Gupta said.

Buy & Sell, Oct 10; top stock picks by Ajit Mishra of Religare Broking

Havells witnessed a sharp rally after a breakout from multi-month consolidation phase. However, in line with market corrective phase, the stock retraced towards the neckline of its previous breakout

Lupin share down 3% as USFDA issues 5 observations for Biotech unit in Pune

Lupin share price slipped in trade after the company announced that United States Food and Drug Administration (USFDA) has issued five observations for its Pune-based Biotech facility.

Lupin inks pact with Scope Opthalmics to market eyecare products in Mexico

Drug maker Lupin on Monday said it has inked a distribution pact with Ireland-based Scope Ophthalmics to market a product range, indicated for the treatment of various eye conditions, in Mexico. The company has signed a distribution agreement with Scope for the registration and marketing of Moist Heat Mask, a Tea Tree Oil Eyelid Cleansing Gel and Tea Tree Oil Eyelid Wipes of the Optase range in Mexico. The products are used for eye conditions like dry eyes, blepharitis and meibomian gland dysfunction (MGD). "This expansion of our ophthalmology range reinforces our commitment to enhancing vision care for our patients, improving their quality of life," said Fabrice Egros, President Corporate Development and Growth Markets, Lupin. Through the signature of this collaboration with Lupin, Scope is expanding its footprint in Latin America, Scope CEO Tom Freyne stated. "Mexico is clearly a country of strategic importance for SCOPE where our innovative eyecare products, together with the